Home > Insider Trading > Filing (0001493152-22-035892)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1862150	Cingulate Inc.	CING	Pharmaceutical Preparations (2834)	863825535

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1883254	J. Shane Schaffer	1901 W. 47Th Place Kansas City KS 66205	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-12-16	10,000	$1.02	41,500	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant to Purchase Common Stock	Acquisiton	2022-12-15	3,642	$0.26	3,642	$6.00
Common Stock	Warrant to Purchase Common Stock	Acquisiton	2022-12-16	200	$0.26	200	$6.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,538	2021-12-10	2026-12-10	No	4	P	Direct
70,738	2021-12-10	2026-12-10	No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	807,828	Indirect	By Fountainhead Shrugged, LLC

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to 1.0199 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth
Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2506 to $0.262 per warrant, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the range set forth.